文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经鼻高流量预氧合用于重症患者气管插管:一项随机临床试验

Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient: a randomized clinical trial.
PubMed 文献 · Intensive Care Med · 2019-01-21
一句话结论在非严重低氧血症的ICU患者快速顺序插管中,与标准球囊面罩氧合相比,经鼻高流量预氧合未改善插管期间最低SpO2,但减少了插管相关不良事件。

PROTRACH研究为随机对照试验,纳入192例ICU需插管的非严重低氧血症患者,随机接受经鼻高流量预氧合(HFNC)或标准球囊面罩氧合(SMO)进行快速顺序插管。HFNC在整个插管过程中持续维持,SMO在喉镜操作时移除。意向治疗分析184例(HFNC 95例,SMO 89例),插管期间最低SpO2中位数HFNC为100% [97; 100],SMO为99% [95; 100],P=0.30,无显著差异。SMO组轻度血氧饱和度下降(低于95%)更常见(23% vs 12%,RR 0.51,95%CI 0.26-0.99,P=0.045),HFNC组不良事件更少(6% vs 19%,RR 0.31,95%CI 0.13-0.76,P=0.007),严重不良事件也更少(6% vs 16%,RR 0.38,95%CI 0.15-0.95,P=0.03)。

要点

  • 在非严重低氧血症的ICU患者快速顺序插管中,HFNC预氧合与SMO相比,插管期间最低SpO2中位数无显著差异(100% vs 99%,P=0.30)。
  • SMO组轻度血氧饱和度下降(低于95%)发生率23%,HFNC组12%,HFNC降低风险(RR 0.51,95%CI 0.26-0.99,P=0.045)。
  • HFNC组插管相关不良事件发生率6%,SMO组19%,HFNC减少不良事件(RR 0.31,95%CI 0.13-0.76,P=0.007)。
  • HFNC组严重不良事件6例(6%),SMO组14例(16%),HFNC减少严重不良事件(RR 0.38,95%CI 0.15-0.95,P=0.03)。
  • HFNC在整个插管过程中持续维持,SMO在喉镜操作时移除,这是两种预氧合策略在操作上的关键区别。

适用人群与场景

  • ICU中需要气管插管的非严重低氧血症患者。
  • 研究纳入需快速顺序插管的ICU患者,排除严重低氧血症患者(原文未列出具体排除标准)。

处置流程与药物剂量

  • HFNC组:经鼻高流量氧疗进行预氧合,并在整个插管过程中持续维持。
  • SMO组:标准球囊面罩氧合进行预氧合,在喉镜操作时移除面罩。
  • 两组均采用快速顺序插管。

研究设计与关键结果

  • 随机对照试验(PROTRACH研究),192例患者随机化,意向治疗分析184例(HFNC组95例,SMO组89例)。
  • 主要终点:插管期间最低SpO2中位数HFNC组100% [97; 100],SMO组99% [95; 100],P=0.30,无显著差异。
  • 轻度血氧饱和度下降(低于95%)发生率SMO组23%,HFNC组12%(RR 0.51,95%CI 0.26-0.99,P=0.045)。
  • 插管相关不良事件发生率HFNC组6%,SMO组19%(RR 0.31,95%CI 0.13-0.76,P=0.007)。
  • 严重不良事件HFNC组6例(6%),SMO组14例(16%)(RR 0.38,95%CI 0.15-0.95,P=0.03)。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 试验注册:ClinicalTrials.gov标识符NCT00321,Eudra CT 2015-A00145-44,CPP 15/13-975,提交日期2016年3月7日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于ICU中非严重低氧血症需快速顺序插管的患者,HFNC预氧合与SMO相比未改善插管期间最低SpO2,但减少了插管相关不良事件(包括严重不良事件),作者结论认为HFNC预氧合导致插管相关不良事件减少。
  • 适用人群为ICU中非严重低氧血症患者,严重低氧血症患者不在本研究纳入范围内。
  • 操作上HFNC在整个插管过程中持续维持,而SMO在喉镜操作时移除,这一差异是实施时需注意的环节。

指南或共识出处

  • PROTRACH研究:Benefits of high-flow nasal cannulae oxygen for preoxygenation during intubation in non-severely hypoxemic patients,ClinicalTrials.gov NCT00321。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Preoxygenation with high-flow therapy by nasal cannulae (HFNC) is now widespread in the intensive care unit (ICU). However, no large randomized study has assessed its relevance in non-severely hypoxemic patients. In a randomized controlled trial (PROTRACH study), we aimed to evaluate preoxygenation with HFNC vs. standard bag-valve mask oxygenation (SMO) in non-severely hypoxemic patients during rapid sequence intubation (RSI) in the ICU.

METHODS: Randomized controlled trial including non-severely hypoxemic patients requiring intubation in the ICU. Patients received preoxygenation by HFNC or SMO during RSI. HFNC was maintained throughout the intubation procedure whereas SMO was removed to perform laryngoscopy. The primary outcome was the lowest pulse oximetry (SpO2) throughout the intubation procedure. Secondary outcomes included drop in SpO2, adverse events related to intubation, and outcome in the ICU.

RESULTS: A total of 192 patients were randomized. In the intent-to-treat analysis, 184 patients (HFNC n = 95; SMO n = 89), the median [IQR] lowest SpO2 was 100% [97; 100] for HFNC and 99% [95; 100] for the SMO group (P = 0.30). Mild desaturation below 95% was more frequent with SMO (23%) than with HFNC (12%) (RR 0.51, 95% CI 0.26-0.99, P = 0.045). There were fewer adverse events in the HFNC group (6%) than in the SMO group (19%) (RR 0.31, 95% CI 0.13-0.76, P = 0.007), including fewer severe adverse events, respectively 6 (6%) and 14 (16%) with HFNC and SMO (RR 0.38, 95% CI 0.15-0.95, P = 0.03).

CONCLUSIONS: Compared with SMO, preoxygenation with HFNC in the ICU did not improve the lowest SpO2 during intubation in the non-severely hypoxemic patients but led to a reduction in intubation-related adverse events.

TRIAL REGISTRATION: Clinical trial Submission: 7 March 2016. Registry name: Benefits of high-flow nasal cannulae oxygen for preoxygenation during intubation in non-severely hypoxemic patients: the PROTRACH study. Clinicaltrials.gov identifier: NCT02700321. Eudra CT: 2015-A00145-44. CPP: 15/13-975 (Comité de protection des personnes de Rennes). URL registry: https://clinicaltrials.gov/ct2/show/record/NCT02700321 .

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Guitton C, Ehrmann S, Volteau C, et al. Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient: a randomized clinical trial. Intensive Care Med. 2019. PMID: 30666367. doi:10.1007/s00134-019-05529-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。